Key result
Integrated nomogram combining non-ECG risk factors and Cornell-voltage duration predicts LVH with ~0.76 AUC.
Why the study?
The authors aimed to establish and validate a user-friendly, clinically practical nomogram for estimating the probability of BSA-indexed echocardiographic LVH among hypertensive patients from northern China.
Does an integrated nomogram combining non-ECG factors and ECG improve the screening for echocardiographic left ventricular hypertrophy in hypertensive patients compared to ECG or non-ECG factors alone?
Cohort (n=4,954)
Does an integrated nomogram combining non-ECG factors and ECG improve the screening for echocardiographic left ventricular hypertrophy in hypertensive patients compared to ECG or non-ECG factors alone?
Answers are grounded in this paper and cite their sources.
An integrated nomogram combining clinical factors and ECG provides a convenient and reliable tool for early identification of left ventricular hypertrophy in hypertensive patients.
OBJECTIVE: We aimed to establish and validate a user-friendly and clinically practical nomogram for estimating the probability of echocardiographic left ventricular hypertrophy (echo-LVH) indexed to BSA among hypertensive patients from northern China. METHODS: A total of 4954 hypertensive patients were recruited from a population-based cohort study from January 2012 to August 2013. The dataset was randomly split into two sets: training (n = 3303) and validation (n = 1651). Three nomograms were initially constructed. That is the Cornell product nomogram, the non-ECG nomogram, and the integrated nomogram which integrated non-ECG risk factors and Cornell-voltage duration product. The least absolute shrinkage and selection operator strategies were employed to screen for non-ECG features. The performance of the nomograms was evaluated using discrimination, calibration, and decision curve analysis (DCA). The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were also calculated. RESULTS: The AUCs, NRIs, IDIs, and DCA curves of the nomograms demonstrated that the integrated nomogram performed best among all three nomograms. The integrated nomogram incorporated age, sex, educational level, hypertension duration, SBP, DBP, eGFR, sleep duration, tea consumption, and the Cornell-voltage duration product. The AUC was 0.758 and had a good calibration (Hosmer-Lemeshow test, P = 0.73). Internal validation showed an acceptable AUC of 0.735 and good calibration was preserved (Hosmer-Lemeshow test, P = 0.19). The integrated nomogram was clinically beneficial across a range of thresholds of 10-50%. CONCLUSION: The integrated nomogram is a convenient and reliable tool that enables early identification of hypertensive patients at high odds of LVH and can assist clinicians in their decision-making.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a cohort in Hypertension (n=4,954). Integrated nomogram (non-ECG risk factors and Cornell-voltage duration product) vs. Cornell product nomogram and non-ECG nomogram was evaluated on Probability of echocardiographic left ventricular hypertrophy (echo-LVH) (AUC 0.758). An integrated nomogram combining non-ECG risk factors and the Cornell-voltage duration product accurately estimated the probability of left ventricular hypertrophy with an AUC of 0.758.
Synapse has enriched 10 related papers. Consider them for comparative context: